Moorfields Eye Hospital NHS Foundation Trust

London EC1V 9EL

1 studies enrolling now · 32 studies all time

What they study most

Achromatopsia, Blindness, Choroidal Melanoma, Diabetes Mellitus, Diabetic Macular Edema, Diabetic Retinopathy, Dry Age-related Macular Degeneration, Eye Diseases, Eye Diseases, Hereditary, Eye Disorders Congenital, Geographic Atrophy, Giant Cell Arteritis

Studies at this site

Extension Study for the Port Delivery System With Ranibizumab (Portal) — Recruiting now
Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION) — Recruiting now
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma — Running, not enrolling
A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration — Running, not enrolling
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease — Running, not enrolling
A Study to Investigate Vamikibart (RO7200220) in Diabetic Macular Edema — Completed
Vamikibart in Participants With Uveitic Macular Edema — Completed
CNGB1 and Allied Disorders — Paused
Efficacy Study of GS010 for Treatment of Vision Loss From 7 Months to 1 Year From Onset in LHON Due to the ND4 Mutation (REVERSE) — Completed
Efficacy Study of GS010 for the Treatment of Vision Loss up to 6 Months From Onset in LHON Due to the ND4 Mutation — Completed
A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Diabetic Macular Edema — Completed
HORIZON: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005 — Stopped early
EXPLORE: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005 — Stopped early
A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration — Completed
A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (TENAYA) — Completed
A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema — Completed
Long-Term Follow-Up Gene Therapy Study for Achromatopsia CNGB3 and CNGA3 — Stopped early
Adalimumab vs. Conventional Immunosuppression for Uveitis Trial — Completed
REC 0/0559 Eye Drops for Treatment of Moderate and Severe Neurotrophic Keratitis in Adult Patients — Completed
Gene Therapy for X-linked Retinitis Pigmentosa (XLRP) - Retinitis Pigmentosa GTPase Regulator (RPGR) — Completed
A Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2 - Protocol A — Completed
Safety and Efficacy of Emixustat in Stargardt Disease — Completed
Long-Term Follow-Up Gene Therapy Study for Leber Congenital Amaurosis OPTIRPE65 (Retinal Dystrophy Associated With Defects in RPE65) — Completed
A Study to Evaluate THR-149 Treatment for Diabetic Macular Oedema — Completed
Gene Therapy for Achromatopsia (CNGB3) — Completed
Gene Therapy for Achromatopsia (CNGA3) — Completed
A Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-dose of Sepofarsen (QR-110) in LCA10 (ILLUMINATE) — Running, not enrolling
Study to Evaluate the Efficacy and Safety of Filgotinib in Adults With Active Noninfectious Uveitis — Stopped early
Clinical Trial of Gene Therapy for the Treatment of Leber Congenital Amaurosis (LCA) — Completed
An Efficacy and Safety Study of Tocilizumab (RoActemra/Actemra) in Participants With Giant Cell Arteritis (GCA) — Completed
A Study Investigating the Safety and Efficacy of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration — Stopped early
A Study of Disease Progression in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration — Stopped early